arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Aligos Therapeutics, Inc.

ALGS

$5.57 ▲ +0.01 (+0.09%) at close

8 Visible periods

22 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Weak

Bearish

auto_awesome

Analytical Summary

Aligos Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $55.1M

Dividend Yield —

Revenue Growth -39.5% ↗

Op. Margin —

ROIC -166.5% ↘

FCF / Share $-8.35 ↗

Trailing P/E —

Price / Book 0.6x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$2.19M

↓ -39.5% —

Net Income Profit after all expenses

$-24.19M

↑ +81.6% —

FCF / Share Free cash flow per share

$-8.35

↑ +35.3% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue Growth YoY (%)	-39.5% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-593%)	-41.7% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-621%)	—	—	—	—	—	—
EPS Growth YoY (%)	88.3% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	38.8% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	39.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—
Net Income Growth YoY (%)	81.6% Excellent ↑ Excellent Improving Year-over-year change in net income	-49.6% Weak ↓ Weak Declining Year-over-year change in net income	8.7% Fair ↑ Fair Improving Year-over-year change in net income	25.2% Excellent ↑ Excellent Improving Year-over-year change in net income	-18.2% Weak Weak Year-over-year change in net income	-107.7% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	35.3% Excellent ↓ Excellent Declining Year-over-year change in free cash flow	58.1% Excellent Excellent Year-over-year change in free cash flow	34.5% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Effective Tax Rate (%) (%)	-1.3% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.3% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.9% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—
FCF / Net Income (x)	3.41x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.62x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.84x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.70x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.95x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Return on Invested Capital (%)	-166.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	308.5% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-96.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-94.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-69.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-44.5% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	65.8% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-99.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-127.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-58.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-66.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-54.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-36.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	-36.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-45.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-401%)	—	-95.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-735%)	-92.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-716%)	-69.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-563%)	-49.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-429%)	80.5% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+437%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Net Debt (USD)	$-18.30M	$-37.00M	$-135.70M	$-81.35M	$-186.82M	$-220.38M	$-69.56M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue per Share (USD)	$0.22	$0.58	$2.42	—	—	—	—	—
Basic EPS, GAAP (USD)	$-2.45	$-20.94	$-34.20	$-56.25	—	—	—	—
Free Cash Flow per Share (USD)	$-8.35	$-12.91	$-30.82	$-47.04	—	—	—	—
Book Value per Share (USD)	$8.67	$-0.36	$30.65	$60.52	$108.18	$144.30	$-413.02	—
Tangible Book Value per Share (USD)	$8.67	$-0.36	$30.65	$60.52	$108.18	$144.30	$-413.02	—
Basic Weighted Avg Shares (shares)	9.88M	6.26M	2.56M	1.71M	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Working Capital (USD)	$61.63M	$40.40M	$117.18M	$100.42M	$165.47M	$219.74M	$106.41M	—
Total Equity (USD)	$53.55M	$-28.97M	$92.08M	$103.90M	$184.73M	$220.04M	$-64.89M	$-13.75M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Sales/Revenue/Turnover (USD)	$2.19M	$3.61M	$6.19M	—	$0.00	—	—	—
Depreciation Expense (USD)	$930.00K	$1.03M	$1.56M	$2.31M	$3.02M	$2.73M	$1.40M	—
Net Income, GAAP (USD)	$-24.19M	$-131.21M	$-87.68M	$-96.05M	$-128.33M	$-108.54M	$-52.26M	—
Operating Cash Flow (USD)	$-82.50M	$-80.74M	$-79.00M	$-79.39M	$-115.66M	$-74.26M	$-46.77M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 29 quarters

Aligos Therapeutics, Inc.

Analytical Summary

8-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare ALGS with peers